📊 APUS Key Takeaways
Is Apimeds Pharmaceuticals US, Inc. (APUS) a Good Investment?
Apimeds is in critical financial distress as a pre-revenue pharmaceutical company with $35.1M net losses, $12.2M operating losses, and only $979.5K in cash against $2.1M annual burn rate. Current ratio of 0.90x combined with negative operating cash flow creates severe liquidity risk with approximately 5 months of runway, indicating potential insolvency without immediate financing or revenue generation.
Apimeds Pharmaceuticals US appears to be a pre-revenue pharmaceutical company with no demonstrated commercial operating base, negative operating cash flow, and recurring losses that remain large relative to its asset base. The balance sheet is currently clean, with high liquidity, substantial cash relative to liabilities, and no meaningful leverage, but the business is still fundamentally dependent on turning R&D and development activity into eventual revenue before cash burn materially erodes that cushion.
Apimeds Pharmaceuticals US, Inc. Key Strengths (APUS)
- Low leverage with 0.00x debt-to-equity ratio and only $14.7M in liabilities
- Substantial asset base of $141.2M provides some balance sheet cushion
- Clean capital structure without significant long-term debt burden
- Very strong liquidity profile with a current and quick ratio of 8.34x
- Low financial risk today due to minimal liabilities and effectively no long-term debt
- Cash of $6.99M provides a near-term operating runway relative to current obligations
APUS Stock Risks: Apimeds Pharmaceuticals US, Inc. Investment Risks
- Zero revenue indicates failed commercialization or pre-clinical stage with no viable product pipeline generating sales
- Critical liquidity crisis with current ratio of 0.90x and cash position of only $979.5K creating imminent solvency concerns
- Accelerating losses with net income deteriorating 331.7% year-over-year while burning $2.1M in operating cash monthly
- Estimated cash runway of approximately 5 months at current burn rate with no positive free cash flow generation
- Absence of insider purchases in past 90 days suggests management lacks confidence in company viability
- Pre-revenue pharmaceutical company facing typical development risks with deteriorating financial position
- No reported revenue or gross profit indicates unproven commercialization and weak growth quality
- Operating cash outflow of $5.11M and free cash flow of -$5.14M imply ongoing cash burn
- Negative ROE of -59.4% and ROA of -52.4% show poor capital efficiency and sustained unprofitability
Key Metrics to Watch
- Cash position and monthly burn rate (immediate solvency indicator)
- Revenue generation and path to commercialization (essential for survival)
- Operating cash flow trajectory and timeline to cash flow breakeven
- Debt covenant compliance and refinancing needs or bankruptcy risk
- Pipeline progress and clinical trial results for drug candidates
- Quarterly operating cash burn versus cash balance
- Any emergence of revenue and improvement in operating loss trend
Apimeds Pharmaceuticals US, Inc. (APUS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
APUS Profit Margin, ROE & Profitability Analysis
APUS vs Healthcare Sector: How Apimeds Pharmaceuticals US, Inc. Compares
How Apimeds Pharmaceuticals US, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Apimeds Pharmaceuticals US, Inc. Stock Overvalued? APUS Valuation Analysis 2026
Based on fundamental analysis, Apimeds Pharmaceuticals US, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Apimeds Pharmaceuticals US, Inc. Balance Sheet: APUS Debt, Cash & Liquidity
APUS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Apimeds Pharmaceuticals US, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.18 indicates the company is currently unprofitable.
APUS Revenue Growth, EPS Growth & YoY Performance
Apimeds Pharmaceuticals US, Inc. Dividends, Buybacks & Capital Allocation
APUS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Apimeds Pharmaceuticals US, Inc. (CIK: 0001894525)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APUS
What is the AI rating for APUS?
Apimeds Pharmaceuticals US, Inc. (APUS) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APUS's key strengths?
Claude: Low leverage with 0.00x debt-to-equity ratio and only $14.7M in liabilities. Substantial asset base of $141.2M provides some balance sheet cushion. ChatGPT: Very strong liquidity profile with a current and quick ratio of 8.34x. Low financial risk today due to minimal liabilities and effectively no long-term debt.
What are the risks of investing in APUS?
Claude: Zero revenue indicates failed commercialization or pre-clinical stage with no viable product pipeline generating sales. Critical liquidity crisis with current ratio of 0.90x and cash position of only $979.5K creating imminent solvency concerns. ChatGPT: No reported revenue or gross profit indicates unproven commercialization and weak growth quality. Operating cash outflow of $5.11M and free cash flow of -$5.14M imply ongoing cash burn.
What is APUS's revenue and growth?
Apimeds Pharmaceuticals US, Inc. reported revenue of N/A.
Does APUS pay dividends?
Apimeds Pharmaceuticals US, Inc. does not currently pay dividends.
Where can I find APUS SEC filings?
Official SEC filings for Apimeds Pharmaceuticals US, Inc. (CIK: 0001894525) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APUS's EPS?
Apimeds Pharmaceuticals US, Inc. has a diluted EPS of $-2.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is APUS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Apimeds Pharmaceuticals US, Inc. has a C grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is APUS stock overvalued or undervalued?
Valuation metrics for APUS: ROE of -27.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is APUS's AI grade for 2026?
Our dual AI analysis gives Apimeds Pharmaceuticals US, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APUS's free cash flow?
Apimeds Pharmaceuticals US, Inc.'s operating cash flow is $-2.1M, with capital expenditures of $9.4K.
How does APUS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -27.7% (avg: 15%), current ratio 0.90 (avg: 2).